ImmunityBio, Inc. (IBRX) Profit Margins
Over the twelve months to 2026-06-30, ImmunityBio, Inc. (IBRX) had operating margin -151.9%, net margin -598.6%, free cash flow margin -174.0%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBRXImmunityBio, Inc.Follow IBRX — free
—
Price chart with a free account
- Market cap
- 8.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 99.3% | — | |
| Operating margin | — | -282954.5% | -220266.7% | -209338.3% | -7095.9% | -36509.1% | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% | -151.9% | |
| Net margin | -100371.2% | -274565.9% | -214273.3% | -204736.2% | -7165.2% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% | -598.6% | |
| FCF margin | -11672.0% | -102620.5% | -185766.7% | -162729.8% | -7102.5% | -28660.0% | -32974.5% | -173196.3% | -63881.2% | -2700.1% | -272.9% | -174.0% |
USD millions · SEC XBRL
ImmunityBio, Inc. — questions
- What is ImmunityBio, Inc.'s operating margin?
- -151.9% over the twelve months to 2026-06-30.
- What is ImmunityBio, Inc.'s net profit margin?
- -598.6% over the twelve months to 2026-06-30.
Every figure on this page comes from ImmunityBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.